The organism responsible for meningococcal disease is of the genus Neisseria meningitidis, also known as Meningococcus. N.meningitidis epidemics have been described for at least 200 years. N.meningitidis was the likely pathogen that caused the meningitis that swept through the Napoleonic armies between 1805-1810, and an epidemic of "Spotted fever" in New England 1 . Epidemics continued to occur every 8 to 15 years for the next 150 years, eventually spreading from Europe and America to the rest of the world.
Major epidemics of Neisseria meningitis are usually caused by Group A, and less commonly by Group C organisms. Meningococcal meningitis has a case fatality rate of 25% during these epidemics in Africa. Epidemics also occur every 7 to 10 years in Sub-Saharan Africa in the so-called meningitis belt, a broad savannah region stretching from The Gambia to Ethiopia, and uniquely susceptible to Group A meningococcal epidemics. Increasing levels of endemic meningococcal disease have been reported from many other parts of the world including the United Kingdom, Norway, Cuba, Brazil, other parts of Africa and Australia 2,3 . The reasons for the occurrence of epidemics and the comparative rarity of meningococcal infection in certain parts of the world is not clear.
In industrialized countries the highest rates of meningococcal infection occur in young infants 4 . Group A meningococcus epidemics, however, often affect older cohorts, with age specific attack rates being higher for 5-to 10-year-olds than for younger children 5 , and also for lower socioeconomic classes.
The clinical spectrum of meningococcal infection is wide. The most common manifestation is asymptomatic carriage of the organism, often in the nasal mucosa 6 . Potentially pathogenic meningococci are present in the nasal mucosa of 2-10% of asymptomatic healthy people with only a small minority of patients developing disease 7 . Meningococcal carriage rates do not necessarily correlate with the risk of invasive disease. N.meningitidis is a uniquely human pathogen, and is spread by person to person transmission of respiratory secretions.
The clinical manifestations of disease vary from transient bacteraemia through illnesses involving joints and skin to the more serious meningitis or even fulminant meningococcaemia and death 8 .
This review will concentrate upon diagnosis, assessment and management of the most severe form of meningococcal infection, namely meningococcal septic shock (meningococcaemia). Recent research into the pathogenesis of sepsis has resulted in the development of a number of potential therapies for the management of endotoxaemia and shock. The role of these modalities in the management of meningococcaemia will be discussed.
BACTERIOLOGY
The meningococcus is one of the two major pathogenic species in the genus Neisseria. It is a Gramnegative, oxidase-positive, aerobic diplococcus which structurally resembles other Gram-negative bacteria. Pathogenic strains of meningococcus have a polysaccharide capsule, the presence of which correlates with pathogenicity. This capsule which is outside the outer membrane of the bacterium is composed of acidic polysaccharide, is highly antigenic and forms the basis for the major epidemiological subdivision of meningococci, i.e. serogroups. These are classified as serogroups A, B, C, D, 29E, H, I, K, L, W135, X, Y, Z. Of these serogroups, serogroups B and C are the most common pathogens, and virtually all epidemics have been caused by serogroups A, B, and C. The meningococcus can be further subdivided into types, subtypes and immunotypes according to certain other membrane proteins and lipo-oligosaccharides 2,9 . N.meningitidis is a saprophyte which colonizes the majority of humans at some stage during life, without producing symptoms. The mechanism of invasion of the bloodstream is not clear, but when it occurs is almost certainly within days of colonization.
PATHOGENESIS OF MENINGOCOCCAL DISEASE
The development of disease following exposure to meningococcus depends upon a complex interaction between the genetic make-up of both organism and host, and also with the environment. Little is known of the host factors that influence the bacterial invasion of mucosal surfaces, but once invaded, disease pattern is determined by the subsequent host response.
Factors affecting the host response
Host response to meningococcal infection consists of specific and nonspecific immune responses. The most important host factor in prevention of meningococcal disease is specific immunity, i.e. the ability to mount an appropriate humoral bactericidal antibody response to infection 10 . Serum bactericidal antibody initiates activation of complement and other cytotoxic mediators which destroy the bacterium. Immunity is frequently acquired transplacentally, conferring protection for about six months. In developed countries, meningococcal attack rates are highest in 8-to 12-month-old infants, the age at which maternally derived antibodies are lost. The incidence falls as bactericidal activity (i.e. immunity) increases with increasing age. The high rate of asymptomatic carriage of potentially pathogenic N.meningitidis and low rate of invasive disease may be due to development of cross-protective antibodies following exposure to nonpathogenic Neisseria species during childhood [10] [11] [12] . These confer protection until a specific immune response to the pathogenic organism develops 11 . The nonspecific host response involves complement activation and normal reticulo-endothelial function. Bactericidal antibody efficacy is reduced by deficiencies of, a) complement 13 ; meningococcal disease is the most common infection in complementdeficient patients [14] [15] [16] , b) blocking IgA antibody, and c) IgM. These latter two abnormalities both result in inadequate complement binding, and thus reduce bactericidal activity. The genetic control of the host acute phase response and level of cytokine responses, particularly generation of tumour necrosis factor α (TNFα) and interleukins 1 and 6 (Il-1, IL-6), may be important to outcome 2, 17, 18 .
Epidemiological factors affecting the organism
The epidemiology of infection with the various serogroups of meningococcus is different. Further classification by serotype allows better understanding of the local epidemiology of carriage and infection with meningococcus because within a serogroup not all serotypes are pathogenic. However, it seems that carriage of a meningococcus, whether pathogenic or not, confers passive immunity to meningococci of the same serogroup and serotype. Variations in virulence between strains of N.meningitidis also contribute to patterns of infection. In general, pathogenic serogroup B meningococcus causes a pattern of persistent disease of low incidence lasting for many years within a population 19 , and it is the most common cause of outbreaks of meningococcal infection in developed countries 20, 21 . Recent reports, however, suggest an increasing incidence of Group C infection in North America 22 . Serogroups A and C, however, have been responsible for many epidemics around the world. Epidemic Group A infections are usually associated with emergence of a new clone, often with new outer membrane protein epitopes, or to transference of particular antigenic clones to areas of low herd immunity, by population movement. Most of the other serogroups mentioned above rarely cause disease and then usually in special circumstances 23, 24 . Complement deficiency predisposes individuals to infection with uncommon meningococcal serogroups (X, Y, Z, W135 and 29E) 25 .
Environment
It is unlikely that nutritional factors play a significant role in the development of disease 26 . Transient environmental factors and seasonal factors 27, 28 and passive and active smoking (particularly in group B cluster outbreaks) 29 have all been linked to increased susceptibility to N.meningitidis infection. Coexistent viral infection which alters the integrity of nasopharyngeal mucosa is also thought to increase susceptibility 7 . Poor socioeconomic conditions such as overcrowding increase transmission rates 30 .
DEFINITIONS
Sepsis, septicaemia, septic shock, sepsis syndrome are all terms that have been used to describe the 198 systemic response to infection that results in hypotension, hypoperfusion, lactic acidosis, obtundation of mental state and oliguria, with or without organ failure. Meningococcaemia, severe meningococcaemia and meningococcal septic shock are all terms used for the presence of "septic shock" and a purpuric rash, in the presence of meningococcal infection. Purpura fulminans describes the presence of severe purpura plus ecchymoses, with vascular thrombosis and gangrene, which in the presence of septic shock is nearly always caused by meningococcal infection. Waterhouse-Friderichsen syndrome or fulminating meningococcal septicaemia are terms used to describe purpura fulminans, septic shock and accompanying bilateral adrenal haemorrhage.
The varying definitions used to describe sepsis in its various guises have been a source of confusion. The American Society of Chest Physicians and Society of Critical Care Medicine agreed on a set of definitions 31 , and these were adapted for paediatric use 32, 33 . A further adaptation has been suggested by Hayden using standard deviation to calculate age-specific parameters. These definitions use parameters and ranges used in the PRISM score 34 (Figure 1 ).
Meningococcaemia can fall into any of the above categories. For the purpose of this review, meningo-coccaemia will be the generic term used to cover all variations of systemic meningococcal infections described by others.
CLINICAL FEATURES OF MENINGOCOCCAEMIA
Meningococcaemia is a distinctive form of generalized Gram-negative septic shock. In its most extreme form the development of purpura fulminans associated with hypotension, disseminated intravascular coagulation (DIC), and multi-organ failure carries a high risk of death or mutilating complications 35 . Bacterial invasion almost certainly occurs within days of mucosal colonization and once invasion has occurred a number of clinical scenarios may occur 36 (Figure 2 ).
Clinical presentation of meningococcal disease is variable and depends upon a number of factors including age, individual resistance factors of the host, and time between onset of disease and presentation to the physician. Often there is a prodromal illness of upper respiratory symptoms in the preceding days. Clinical features will not be discussed in detail, and the reader is referred to standard textbooks for these descriptions 37 .
Acute meningococcaemia can present with or without meningitis. Clinical signs and the characteristic petechial rash of meningococcal disease develop rapidly. The petechial rash may be preceded by a less typical maculopapular eruption. Fever usually develops quickly, followed by malaise, weakness, myalgia, vomiting and headache. Ankles, axillae and 199 wrists are common sites for early petechial lesions. Patients with these symptoms are often haemodynamically stable and may be quite alert. Level of consciousness should not be used as a guide to degree of cardiovascular compromise. The majority of patients (80 to 90%) presenting with these symptoms remain clinically stable and do not deteriorate haemodynamically. Deterioration, however, can occur very rapidly, even after antibiotic therapy has been started, due to release of endotoxin or other bacterial components, partly as a result of antibioticinduced bacteriolysis. The toxic extension of acute meningococcaemia, also known as Waterhouse-Friderichsen syndrome or purpura fulminans, may ensue. This is characterized by high fever, vascular collapse (with marked increase in capillary permeability leading to hypovolaemia), worsening level of consciousness, coagulopathy and development of characteristic dermatological features. The generalized petechial rash becomes purpuric and spreads. Ecchymoses develop and may become confluent and cover large parts of the body. Laboratory findings in meningococcaemia include coagulopathy, thrombocytopenia, neutropenia, (although the white cell count may be normal or elevated), and raised serum lactate. Low ionized calcium is also common.
Waterhouse-Friderichsen syndrome occurs in 5 to 15% of cases of acute meningococcaemia and has a high mortality rate (5 to 28%). The incidence of the various clinical scenarios seen in meningococcal infection has been reported 38, 39 . Meningitis alone occurs in 11 to 49% of patients, 12 to 61% have both meningococcaemia and meningitis and 16 to 28% meningococcaemia only, of which the rate of fulminant meningococcaemia ranged from 5 to 28%.
PATHOPHYSIOLOGY OF MENINGOCOCCAEMIA
The meningococcus breaches the body's defences, invades the blood stream and multiplies. The cellular components of N.meningitidis which contribute to natural immunity are probably capsular polysaccharides, except for the non-immunogenic Group B polysaccharide 40 . The meningococcus continually sheds blebs of its outer membrane 2 . These blebs are rich in lipooligosaccharide, also known as bacterial endotoxin and are central to the development of host response and the eventual degree of disease expression.
When endotoxin, and probably other bacterial components, come into contact with the immune system, they initiate a complex cascade of events cul-minating in the syndrome of meningococcaemia. The initial event in this cascade is the release of primary inflammatory cytokines from macrophages and other inflammatory cells. These cytokines are parakrine agents; they act locally on a variety of tissues signalling information to adjacent somatic tissue 41 . Several studies have confirmed the pivotal role of TNFα, IL-1 and IL-6 in SIRS and septic shock 42, 43 . These mediators are beneficial in the normal inflammatory response.
TNFα increases neutrophil margination, enhancing antimicrobial activity of monocytes, macrophages and neutrophils. It also increases skeletal muscle degradation to produce amino acids for gluconeogenesis and protein synthesis. IL-1 also enhances cellular and microbial activity, promotes beneficial metabolic changes and wound healing 44 . These beneficial effects only occur at appropriate concentrations. Higher concentrations lead to activation of endothelial cells, monocytes and macrophages, and release of other cytokines and mediators of the inflammatory response including acute phase proteins (C-reactive Protein, (CRP) and fibrinogen), anti-inflammatory cytokines (Il-4, Il-8, Il-10) and cyclo-oxygenase products. High concentration of proinflammatory cytokines such as those that occur in acute meningococcaemia produce characteristic physiological responses. These include disruption of thermoregulation, and disturbance of cardiovascular and bone marrow function. Vascular endothelial cell damage also occurs, resulting in marked capillary leak leading to decreased intravascular volume, reduced perfusion, vasoconstriction and finally endorgan damage. The coagulation and complement cascades are also activated 17 .
The involvement of cytokines in meningococcaemia was confirmed in 1987. Waage et al 45 detected TNFα in the sera of patients with meningococcal disease and there was a significant correlation between high TNFα concentrations and mortality 46 . TNFα is released very early in meningococcal infection followed by IL-6 release 1-4 hours later 16 . High levels of IL-6 in the presence of IL-1 were associated with a fatal outcome 47 , and levels of IL-6 were considerably higher in patients with septicaemic shock than with meningitis or combined meningitis/ septicaemic shock 48 . TNFα and IL-1 also stimulate production of specific anticytokine substances such as interleukin-1 receptor antagonist (IL-1ra) and circulating TNFα receptors (TNFα r1, TNF r2) 49, 50 . These compounds are thought to inhibit the proinflammatory effects of TNFα and Il-1, and may have potential in the treatment of septic shock.
IL-1ra is a naturally occurring protein synthesized by a number of inflammatory cells in response, which blocks Il-1 activity by competitively binding to Il-1 receptor binding sites 51 . TNFα receptors are present on cellular surfaces and are shed from cell surfaces during septic shock forming a pool of circulating free TNFα receptors. These circulating receptors bind circulating TNFα and prevent it from binding to the cellular TNFα receptors, thus providing endogenous inhibition of TNFα activity. Shedding of cellular receptors during sepsis also helps to attenuate TNFα activity by reducing the number of cellular bound TNFα receptors. The relationship between TNFα and circulating TNFα receptors in meningococcaemia has been investigated 52, 53 . At TNFα concentrations up to 500 pg/ml (normal TNFα levels <25 pg/ml), levels of TNFα r1 and TNFα r2 correlate well with TNFα levels. At higher TNFα levels the receptor concentrations do not rise, leaving a surplus of TNFα unbound. TNFα is present in high concentrations early in disease, but levels fall rapidly, whereas TNFα receptor levels remain constant 54 . This suggests that a high ratio of TNFα to TNFα receptors early in meningococcaemia allows widespread initiation of the actions of TNFα. Such imbalance between TNFα and TNFα receptors contributes to mortality 53 . Another anti-inflammatory cytokine, Il-10, acts by inhibiting endotoxin mediated Il-1 and TNFα production. High levels of Il-10 were found in children with meningococcaemia 55 . Production of these antiinflammatory cytokine mediators early in disease may be a protective response to acute cytokine rises in meningococcaemia.
As disease severity and outcome in meningococcaemia appear to be related to free TNFα levels in the serum, certain questions arise. Would anti-TNFα immunotherapy be beneficial in fulminant meningococcaemia and is it possible to predict outcome from early TNFα assay? Also, Il-1 appears to be produced only in cases of fulminant meningococcaemia. Would anti-interleukin 1 therapy be of any use? The use of these treatments is discussed later.
TNFα assay is not yet available to the physician at the bedside, taking several hours to perform. Hazelzet et al 56 assayed cytokine levels (Il-1 and Il-6, TNFα, TNFα r1 and 2), lactate, CRP and fibrinogen sequentially over time in patients with meningococcaemia. They found a clear relationship between serum TNFα and Il-6 levels, serum lactate and severity of disease. A log-linear relationship between lactate and cytokine levels was also found suggesting that lactate could be used as an indicator of cytokine levels. Also lactate and cytokine levels were correlated to disease severity and to PRISM score 57 , indicating that serial lactate measurements may be useful in outcome prediction. This is in agreement with previously published reports on lactate measurements as an indicator of disease severity in cases of shock in general 58 .
COAGULOPATHY
The association between sepsis and coagulopathy is well known. Recent advances in understanding the aetiology of the coagulopathy are leading to new therapeutic possibilities. Failure to manage the coaguopathy associated with meningococcaemia has contributed to the lack of improvement in morbidity caused by this condition 33 . The finding of coagulation abnormalities in patients with meningococcaemia is almost invariable, and the development of purpura fulminans is the hallmark of fulminant meningococcal disease. About 10% of patients with meningococcaemia suffer autoamputation or soft tissue destruction as a result of intravascular thrombosis, coagulopathy and cutaneous haemorrhage 59 .
Purpura fulminans is not unique to meningococcaemia and is seen in three main clinical settings: 1) in the neonate as a result of deficiency in Protein C or Protein S, 2) in acute infectious purpura fulminans, of which meningococcaemia is the most common cause, and 3) as a rare post-infectious syndrome following a viral or bacterial illness. Other rare associations are with cholestasis, warfarin-induced skin necrosis, antiphospholipid syndrome, and heparin-induced thrombocytopenia 60 . Purpura fulminans is accompanied by thrombosis and haemorrhage in other organs such as adrenal, kidney and lung. Histologically, the cutaneous lesions in purpura fulminans reveal microvascular thrombosis involving the dermis with surrounding perivascular haemorrhage. Clinically the lesions develop from purpuric to ecchymotic and then to more circumscribed black/purple skin lesions with haemorrhagic bullae. Ultimately gangrene develops 61 .
The mechanism of development of DIC and purpura fulminans in meningococcaemia is uncertain. The underlying pathophysiological process involves attachment of endotoxin to vascular endothelium. Normally, endothelial cells act as both inhibitors and activators of the fibrinolytic system. In vitro, endotoxin has been shown to change vascular endothelial function to procoagulant and antifibrinolytic 62 . This results in fibrin deposition in the microvasculature with endothelial damage causing DIC, intravascular thrombosis and haemorrhagic necrosis of the skin. The particular propensity for meningococcal endo-toxin to cause microvascular damage in the skin, and to a lesser extent in the adrenal medulla, may be due to either 1) the Schwartzman reaction, a nonimmunologically mediated phenomenon resulting in fibrin deposition in capillaries in response to a second challenge from endotoxin occurring 24 hours or so after initial exposure to endotoxin, (it seems that sensitization occurs in skin during the initial bacteraemia with a later challenge during acute endotoxaemia causing the reaction 63 ), or 2) site-specific differences in endotoxin mediated cytokine release from endothelial cells. Cytokines cause endothelial cells to release a tissue factor, a procoagulant, which activates all coagulant proteins, including platelet activating factor and von Willebrand factor. TNFα downregulates the expression of thrombomodulin, an endothelial cell glycoprotein which blocks the procoagulant activity of thrombin 64, 65 , and results in activated procoagulation and disproportionately decreased circulating anticoagulant activity 66 .
The activation of coagulation in meningococcaemia seems to be primarily dependent upon extrinsic pathway activation 67 either via TNFα or Il-1 inducing tissue factor expression 68 , or by exposure of subendothelial tissue factor to blood as a result of increased vascular permeability 69 .
Fibrinolysis is initially activated and then rapidly suppressed in the septic patient with DIC. Experimental infusion of TNFα is followed by an increase in tissue plasminogen activator (TPA) and urokinase (UPA) levels 70 . These increases are short-lived and within an hour levels decline and levels of plasminogen activator inhibitor rise, inhibiting the fibrinolytic activity of plasminogen. Within four hours, fibrinolytic activity ceases resulting in inadequate removal of fibrin deposition. The fibrinolytic response is mediated by TNFα.
Both Protein C and Antithrombin III levels are low in patients with DIC and Gram-negative sepsis at admission and for up to a week afterwards 71 . There is a significant difference in the rate of normalization of these factors between survivors and non-survivors, which only becomes apparent over time.
In conclusion, poor outcome in meningococcaemia is correlated with a stronger activation of coagulation and more marked inhibition of fibrinolysis. Prolonged depression of Protein C and Antithrombin III levels have also been demonstrated and are positively correlated with death in other studies 72, 73 , and acquired Protein C deficiency has been correlated with size of skin lesions in purpura fulminans, suggesting it may be related to the pathogenesis of purpura fulminans 74 . The therapeutic implications of Protein C and Antithrombin III are discussed later.
MANAGEMENT
Speed of diagnosis, transfer to a facility capable of providing appropriate intensive care, treatment of hypovolaemia, hypotension, acidosis and respiratory impairment are the keys to improving outcome in meningococcaemia.
Cardiovascular disturbances in meningococcaemia
There are two major disturbances contributing to cardiovascular instability in meningococcaemia [75] [76] [77] [78] [79] .
1) Hypovolaemia. Patients with meningococcaemia have a profound depletion of intravascular volume. This is compensated for by intense vasoconstriction, and normotension is no indicator of volume status. That the finding of the hypotension is associated with poor outcome 78 is not surprising as it indicates decompensated severe disease. If the patient is distant from an intensive care unit, it is vital that resuscitation is commenced prior to transfer. Secure venous access must be obtained early; this may prove difficult in a hypotensive, hypovolaemic infant. If intravenous access is not easily obtained, an intraosseous needle should be inserted or venous access secured via a cutdown. Hypovolaemia is due to marked capillary leak 79 . Correction of hypovolaemia may require large volumes of fluid, of the order of 50 to 75% of blood volume over a few hours.
Rapid correction of volume status is mandatory, and the use of colloid solutions is recommended. Fresh frozen plasma has been advocated to provide volume and replace coagulation factors. A recent study 80 , however, found a statistically significant correlation between administration of blood or fresh frozen plasma and increased mortality, as compared to artificial colloids. The reasons for this were not clear, but may be related to citrate toxicity. Patients whose hypovolaemia is not rapidly corrected have a very poor prognosis.
2) Cardiac dysfunction. Cardiac function has been shown to return to normal over 72 hours in survivors but remains very depressed in non-survivors 81 . This dysfunction is characterized by decreased cardiac index, increased pulmonary capillary wedge pressure, but normal left ventricular size. The mechanism of cardiac dysfunction is multifactorial. Endotoxin causes direct myocardial depression, and myocardial compliance is decreased 79 as a result of myocardial oedema possibly caused by calcium, complement or histamine. Release of a specific myocardial depressant factor or acidosis may also contribute.
Hypotension appears to be due to major capillary leakage and myocardial failure rather than to vasodilatation, unlike other forms of septic shock. Systemic vascular resistance has not been found to be low. Alternatively, it may be that disease progression is so rapid that the hypodynamic stage of septic shock has been reached by the time monitoring is established. The optimum management is preload augmentation and the early use of catecholamines to optimize cardiac function. Cardiac function normalizes only slowly and inotropic support may be needed for several days. Excessive fluid administration may exacerbate cardiac failure and cause pleural effusions, ascites and peripheral oedema. Limb oedema may further compromise circulation to the limbs.
Respiratory factors
Hyperventilation to compensate for metabolic acidosis is a feature of septic shock, including meningococcaemia. This increases work of breathing and oxygen consumption markedly. Early use of mechanical ventilation will eliminate work of breathing, and mechanical ventilation with sedation and paralysis is particularly useful in the agitated child to facilitate intravascular access and monitoring. It may also be indicated by altered mental state, suspected increased intracranial pressure (ICP), hypoventilation, hypoxaemia and pulmonary oedema. A degree of hyperventilation will be required to maintain an acceptable pH.
Venous access
Venous access may be very difficult in shocked patients, particularly young children. Secure venous access is absolutely vital, and as discussed above must be established early. Consideration should be given to the likely progression of disease when inserting lines; it may be preferable to have one large-bore, multilumen central venous catheter than a number of smaller peripheral cannulae. Invasive therapy such as plasmapheresis requires a large-bore double-lumen central venous catheter. It should be remembered that thrombolytic therapy is likely to precipitate bleeding from any arterial or venous puncture site.
In children in particular, insertion of a central venous catheter by an experienced person may prevent repeated peripheral stabs. Insertion of an intraarterial catheter may be difficult or impossible in the initial stages of the disease, but is important for monitoring. A cutdown procedure may be preferable to reduce arterial damage and haematoma formation. The site of arterial cannula placement should also take into account the possibility of limb ischaemia and gangrene. Although it would seem that inserting an intra-arterial cannula into an artery supplying an already compromised area of tissue would be contraindicated, in practice blood supply does not appear to be compromised. There is a potential advantage in placing an arterial cannula into the worst affected limb, to facilitate the use of low dose local thrombolytic therapy.
Early planning of the site and number of venous and arterial cannulae likely to be required is desirable. This planning should include consideration of limb involvement, the possible need for thrombolytic therapy and problems of inserting lines later, when limbs are oedematous. The insertion of multiple cannulae in the presence of coagulopathy is also hazardous. Surgical assistance is sometimes required.
PROGNOSTIC INDICATORS AND SCORING SYSTEMS IN ACUTE MENINGOCOCCAL INFECTION
Because of the potential for sudden rapid deterioration in the patient's condition and the high morbidity and mortality associated with meningococcaemia, it has long been recognized that the early prediction of outcome is vital. The development of prognostic indicators and scoring systems designed to predict both morbidity and mortality in meningococcal disease has helped to identify those patients who have an excellent chance of recovery with antibiotic therapy alone and also those patients who require a much higher level of intervention. Being able to reliably predict patients at risk of development of organ system failure or death may help the physician in making decisions such as the need for transfer of patients to tertiary referral centres or admission to intensive care units for closer observation and early initiation of invasive monitoring.
A number of scoring systems are very sensitive at predicting mortality (a high percentage of patients who die are predicted to die), but positive predictive value (percentage of those who are predicted to die who do die) is less accurate. The value of scoring systems in predicting individual case mortality is therefore limited. Although it has been suggested that scoring systems should not determine the level of care provided for patients with meningococcaemia, in general, scores predicting poor outcome should be regarded as an indication for highly aggressive management 74 .
Development of Scoring Systems
The first scoring system reported for meningococcal disease was that of Stiehm and Damrosch 82 (Figure 3) .
The presence of three or more of these features indicated a >85% chance of dying. Patients with two or less had a fatality rate of <10%. Niklasson et al 83 confirmed these findings. Lewis in 1979 84 found that coma, systolic blood pressure <75 mmHg under four years of age and <85 mmHg over four years of age, or both, correlated with high mortality. Other studies have found that thrombocytopenia (platelet count <100x10 9 /l), low WBC (<10x10 9 /l), shock as defined by blood pressure <100 mmHg in adults or <70 mmHg in children, serum potassium >5 mmol/l, or serum pH <7.35 correlated with poor outcome 85, 86 .
A comprehensive statistical review by Gedde-Dahl et al 75 of several previously published scoring systems came to a number of conclusions. (Figure 4 ).
These workers recommended that time-related factors not be used in scoring systems because they depend on how quickly the condition is recognized and the amount of time it takes to bring the patient to hospital, and proposed a purely clinical scoring system using age-adjusted systolic blood pressure, cyanosis, ecchymoses, diarrhoea before or at admission, cold extremities, absence of nuchal or back rigidity and rectal temperature of at least 40°C. The Glasgow meningococcal septicaemia prognostic score (GMSPS) 87 is a clinically based scoring system that can be calculated rapidly and repeated frequently if required and is used to predict likely mortality in the intensive care unit. (Figure 5) .
A score of >7 out of 15 had a specificity of 100% and a positive predictive value of 100% in both retrospective and prospective studies 87 . GMSPS was reevaluated 88, 89 , and the following conclusions reached: a threshold value of greater than or equal to 9 provided a sensitivity of 100%, specificity of 95% and positive predictive value of 74%. Outcome may alter either as a result of advances in treatment and management, or a change in the nature of the disease. For this reason, periodic reevaluation of scoring systems that predict mortality is important. A scoring system that is simply and accurately compiled is advantageous as it will be reproducible, allowing comparisons to be made between institutions and across time. It also allows different treatment modalities to be evaluated 90 . Recent reevaluation of GMSPS showed that its positive predictive value may have changed. Shah and Mathew 91 found that while the sensitivity of the GMSPS remained 100%, the positive predictive value (the percentage of all the patients above the threshold level who died) has fallen to 38% if the threshold value is >7 or 45.5% if the threshold value is >9. In 1992 Thompson et al 38 found the positive predictive value of the GMSPS was only 36% for a value greater than 8. The reasons for improved survival in patients with meningococcaemia predicted to die has not been fully evaluated but it is likely to be due to improved quality of management (aggressive volume replacement, ventilation, inotropic support) and possibly some of the newer therapies that have been introduced in recent years. Re-evaluation 36 of the Stiehm and Damrosch criteria 83 also found that the scoring system was accurate in identifying patients with a good outcome but less good at predicting poor outcome. In this more contemporary study patients were aggressively treated with intensive care, ventilation, pressor agents and steroids and it was suggested that the reduced mortality was due to this aggressive treatment. They also found that the absence of meningeal involvement was not a good predictor of mortality, 204 N. J. KENNEDY, A. W. DUNCAN Anaesthesia and Intensive Care, Vol. 24, No. 2, April 1996 Features associated with poor prognosis 1. Inset of petechiae within 12 hours prior to admission 2. Normal or low leucocyte count (white cell count) 3. Normal or low erythrocyte sedimentation rate (ESR) 4. Absence of meningitis 5. Shock 1. Blood pH of <7.35 was the best single factor predict ing fatal outcome followed by: thrombocytopenia low WBC count (<10 x 10 9 /l) hypotension and clinically observed cyanosis and ecchymoses.
2. Fatality rate amongst those aged 5-19 years was less than half of that in younger and older patients with meningococcal disease.
3. Onset of skin haemorrhage within 12 hours before admission to hospital appeared to be no better indicator than the presence of skin haemorrhage on admission. and that a low white count, presence of rash and altered mental status, particularly coma, were sensitive indicators of mortality. None of the scoring systems so far developed accurately predict the longterm serious morbidity resulting from severe meningococcal infection, such as permanent neurological damage and limb gangrene. Such a system would be very useful.
Studies examining factors which help identify patients at risk of organ failure or death in meningococcaemia include the following.
1) A retrospective and then prospective analysis of paediatric patients 92 which identified patients at risk of organ system failure and death in acute meningococcaemia. It concluded that signs of circulatory insufficiency, a peripheral WBC count <10,000 cells/ mm or a coagulopathy were strong prognostic indicators for developing organ system failure. In the absence of coagulation studies, clinical manifestations of vasculitis and coagulopathy (such as purpura or ecchymoses) should be considered as evidence of coagulopathy. All patients who subsequently developed organ system failure exhibited one or more of the three major identified prognostic factors for organ system failure. All patients who developed multiple organ system failure died.
This study also found that the absence of meningeal inflammation, as indicated by the absence of meningismus or CSF WBC count of <20 cells/ mm 3 , was associated with poor outcome, and PRISM score 58 was remarkably accurate at predicting death as an outcome in meningococcaemia. PRISM score is, however, unlikely to be useful as an acute predictor of outcome in meningococcaemia, as it is calculated over 8 to 24 hours.
2) A retrospective study of paediatric patients with meningococcaemia or systemic inflammatory response syndrome with purpura that examined the presence or absence of coagulopathy as a predictor of outcome in meningococcaemia 93 . Outcome in this study was defined as either death or serious morbidity. Serious morbidity referred to serious debilitating or disfiguring injury, including permanent neurologic damage, limb or digit amputation and skin loss with the requirement for reconstructive surgery ( Figure 6 ).
The overall conclusion was that a severe coagulopathy (partial thromboplastin time >50 seconds or serum fibrinogen concentration <150 mg/dl) at referral or on admission to ICU was identified as a strong predictor of poor outcome with the sensitivity of 81%, specificity of 95%, positive predictive value of 93% and negative predictive value of 88% for serum fibrinogen and 95%, 90%, 86%, and 97% respectively for prolonged partial thromboplastin time. Use of a single test that accurately predicts outcome is quite simple and does not have the disadvantages of scoring systems that require multiple data or invasive procedures in order to calculate them. This study also found similar results to other studies when the Niklasson and the Stiehm/Damrosch scoring systems 83, 84 were applied to their patients. When mortality was used as an endpoint these scoring systems were inaccurate, but if mortality and morbidity, as defined above, were used as the endpoint, sensitivity and positive predictive value predictions were very accurate.
Scoring systems currently available for meningococcaemia should be used to determine patient requirements for intensive monitoring, and the need for interventional therapy. A GMSPS score of 8 or greater has been advocated as an indication for using interventional therapies 91 , but this may depend upon resources available 92 .
ANTIBIOTICS FOR MENINGOCOCCAEMIA
N.meningitidis is extremely sensitive to penicillin. Intravenous penicillin G has been the mainstay for antibacterial chemotherapy for meningococcaemia for many years. It should be administered in high dose 4 to 6 hourly, for 5 to 7 days. In some patients, e.g. very young, very elderly, or immunosuppressed patients, the clinical picture of infection with other organisms, including Haemophilus aegyptii, may be identical to meningococcaemia. It is therefore wise to commence treatment with a broad spectrum third generation cephalosporin, such as cefotaxime or ceftriaxone, until sensitivities have been established.
Worldwide, strains of N.meningitidis which are less sensitive to penicillin are becoming more common. Such strains have been found in Greece, U.K., Canada, Spain and South Africa 94 . Interestingly, these resistant strains are not β-lactamase producing. They have a decreased affinity of a bacterial penicillin binding protein for the antibiotic 95 . Cefotaxime or ceftriaxone are suitable alternatives.
There is currently no N.meningitidis reported resistance to penicillin, or to any third generation cephalosporin in Australia 96 . 
IMMUNOTHERAPY IN MENINGOCOCCAEMIA
Meningococcaemia usually has a very rapid onset with characteristic clinical features allowing an early provisional diagnosis and initiation of treatment. Early intervention using anticytokine or antiendotoxin therapy, before the initiation of the physiologically damaging sequelae resulting from acute rises in cytokine levels, may obtund development of end-organ damage. To date no studies looking at the use of passive or active immunotherapy solely in meningococcal infections have been published. Of the studies published concerning endotoxic shock of any aetiology, the use of passive immunotherapy, i.e. polyclonal and monoclonal antibodies have received most attention.
Polyclonal antibodies to the endotoxin core oligosaccharide (a moiety common to pathogenic Gram-negative bacteria), such as the J5 mutant E.coli polyclonal antibody, were postulated to neutralize endotoxin by binding to it. Two studies 97, 98 indicated great promise but other studies failed to show benefit in terms of mortality 99, 100 . One study 100 found no statistically significant improvement in survival in children with circulatory shock and infectious purpura who were treated with J5 immune plasma. A large proportion of these children had meningococcaemia, although results were not reported specifically for the subgroup with meningococcaemia.
The use of a monoclonal antibody (HA-1A) directed against the Lipid A moeity of endotoxin was postulated to provide more specific targeting of endotoxin and to reduce the risks of using polyclonal sera, i.e. infection and serum sickness. After encouraging results 101 showing reduced mortality in Gram-negative septicaemia, further trials failed to show benefit and indeed showed an increase in mortality in the patients subsequently proven not to have Gram-negative sepsis who were given antibody.
Two recent large controlled prospective studies 102,103 have confirmed no decrease in mortality at 28 days, and a probable increase in infection in those patients with Gram-positive infections. Following a number of reports indicating no benefit or even increased mortality from monoclonal antibody therapy in adult patients with Gram-negative sepsis or septic shock, the monoclonal antibody HA-1A was withdrawn from clinical use in Europe from 1993 104 .
There have been individual case reports of meningococcaemia treated successfully by HA-1A 105, 106 . A trial is continuing in France using HA-1A monoclonal antibody solely in children with meningococcaemia. The results of this trial are keenly awaited. Anti TNFα monoclonal antibody has also been shown to reduce mortality in animals suffering experimental endotoxic shock. Trials in human sepsis showed possible benefit in improving survival in patients with high TNFα levels 107 , but recent work showed a benefit in survival only in patients with septic shock. Twenty-eight day mortality was similar 108 .
TNFα receptor infusion in septic shock seems to be potent at neutralizing excessive TNFα. TNFα receptors also attenuated the hypotensive response in a septicaemic rat model 109 . A trial of TNFα receptor therapy in sepsis syndrome, however, found that lowdose TNFα receptors (0.15 µg/kg) conferred no decrease in mortality compared with placebo and also found that high-dose TNFα receptor therapy (0.45 µg/kg or 1.5 µg/kg) actually increased mortality.
Interleukin 1 receptor antagonist (IL-1ra) has not been shown to decrease mortality at 28 days compared with placebo in preliminary results from a multi-centred trial 110 .
The overall future of immunotherapy for any form of septic shock at present appears gloomy. If immunotherapy were to prove useful, meningococcaemia may respond better to its use than other Gram-negative sepsis because of its typical clinical picture allowing earlier diagnosis and treatment, before the systemic cascade has been fully activated. At the present time it does not appear likely that immunotherapy will be any more useful in meningococcaemia than in other forms of Gram-negative sepsis.
Unfavourable results from the trial in France into HA-1A in children with meningococcaemia will probably spell the end for immunotherapy in meningococcaemia.
THE USE OF STEROIDS IN MENINGOCOCCAEMIA
Steroids have been used in the treatment of meningococcal infections for two reasons:
1. To improve audiological and neurological outcome in meningococcal meningitis.
2. To improve survival and outcome in meningococcal septic shock.
There is evidence that dexamethasone reduces white cell count, TNFα concentration and indices of meningeal inflammation in cerebrospinal fluid, and attenuates the rise in levels of TNFα if given before the administration of ceftriaxone (but not after), to patients with Haemophilus influenzae meningitis and pneumococcal meningitis 111, 112 . Studies have shown a beneficial clinical effect of using dexamethasone therapy for children with bacterial meningitis [112] [113] [114] [115] , reducing the risk of bilateral moderate or severe hearing loss only in haemophilus infections. In pneumococcal meningitis, one study found that dexamethasone reduced morbidity and mortality 116 . Two other studies have suggested that steroid treated patients had less adverse neurological outcomes 117, 118 . In meningococcal meningitis 116, 119 there appeared to be an improvement in neurological and audiological outcomes although neither study reached statistical significance.
Most studies advocate giving dexamethasone at or before the time of the administration of the first dose of antibiotics, in order to obtund the rise in cytokine seen with the antibiotic-induced bacteriolysis. Recommended dosages have been 0.15 mg/kg IV, 6-hourly for four days, although a shorter course of dexamethasone (two days instead of four days) was associated with similar neurological and audiological outcomes 119 . This appeared to be the case in meningococcal meningitis as well as Haemophilus influenzae meningitis. The significance of this is not clear, but a shorter course may be associated with less steroid induced side-effects such as gastrointestinal bleeding. The rate of steroid-induced complications is very low 120 .
While the use of dexamethasone in meningococcal meningitis has not been conclusively proven, the Committee on Infectious Diseases of the American Academy of Paediatrics recommends that a two-or four-day dexamethasone regimen be used for meningitis due to Haemophilus influenzae B, and should be considered for infections with Streptococcus pneumoniae and Neisseria meningitidis 121 . A British Working Party 122 recommended the use of dexamethasone only in haemophilus meningitis.
The use of steroids in the treatment of meningococcaemia has also been subject to much debate. Serum cortisol levels are generally elevated in patients with sepsis and septic shock 123 . Adrenal insufficiency has been reported in septic shock but it is not invariable, and the mechanism is not certain. Measurement of the adrenal response to exogenous adreno-corticotrophin in patients with Neisseria meningitidis meningitis or meningococcaemia 124 found that basal plasma cortisol levels were elevated in patients with meningococcal infection. Patients with meningitis and no systemic symptoms had a normal response to adreno-corticotrophin (ACTH), but patients with systemic meningococcal illness has a decreased adrenal response to exogenous ACTH stimulation. Most other data concerning the use of steroids in septic shock come from studies on groups of patients with septic shock of any aetiology. There is evidence that corticosteroids, when administered early and in adequate dosage for brief periods, are associated with modulation of the inflammatory response and improvement in survival 34, 112, 125, 126 . Actions of corticosteroids include inhibition of production of critical proximal cytokines (TNF, IL-1, arachadonic acid metabolites), modulation of complement and polymorphonuclear activation, and decreased endorphin release.
Early studies into the use of high-dose glucocorticoids in patients with septic shock 127 and severe typhoid fever 128 yielded conflicting results. The first study showed that although steroids delayed death they did not reduce overall mortality, while the second study showed a marked reduction in case fatality rates with the use of high-dose glucocorticoids (dexamethasone 1 mg/kg six-hourly for 48 hours). Two more recent multicentred prospective randomized trials in adults failed to show decreased mortality rates in methylprednisolone treated patients with septic shock 129, 130 . However, two recently published meta-analyses reviewed the efficacy of corticosteroid therapy in sepsis 131, 132 . Both studies concluded that corticosteroids did not reduce mortality in patients with septic shock, although one 132 suggested there may be some positive effect in patients with Gram-negative septicaemia. The other 131 found that mortality may be increased in patients with overwhelming infection, possibly due to secondary infection. This study also indicated that there may be some increase in morbidity due to worsening of renal and hepatic function, and that the risk of developing adult respiratory distress syndrome may increase.
Recent work suggests that although cortisol levels are almost invariably increased in septic shock, these high levels may, in fact, represent an inadequate adrenal response to the degree of insult 123 . The term "relative adrenocortical insufficiency" was suggested by Schein et al 123 , who determined that absolute hypocortisolaemia is rare but relative hypocortisolaemia is more common. They also established that serum cortisol levels are not proportional to vasopressor drug levels. Rothwell et al 133 found that the rise in serum cortisol in response to administration of ACTH was relatively normal in patients who survived septic shock, but markedly reduced in all patients who died of septic shock. Soni et al 134 measured the adrenal response to exogenous ACTH stimulation in patients with septic shock and found that 24% had relative adrenal insufficiency. These patients were administered intravenous glucocorticoids and exhibited marked improvement in cardiovascular parameters over a short period of time. There was, however, no difference in longterm mortality between patients with adrenal insufficiency treated with glucocorticoids and patients with a normal adrenal response. Cytokine levels were also measured, and it was found there was no difference in TNFα levels between patients with normal and abnormal adrenal responses, although Il-6 levels were lower in patients with adrenal insufficiency. The administration of ACTH did not alter cytokine levels significantly.
More recently 135 low dose hydrocortisone infusion (10 mg/hour in adults), which corresponds to the maximum secretory rate of cortisol achieved by ACTH stimulated normal subjects, has been shown to reduce the systemic inflammatory response and normalize blood pressure after two days of treatment as compared to placebo. This effect disappeared after withdrawal of exogenous hydrocortisone.
Thus although the use of glucocorticoids in septic shock, including meningococcaemia, has been shown almost certainly not to improve outcome, there is evidence that corticosteroids may be beneficial in a subgroup of patients. This sub-group of patients with relative adrenal insufficiency may show a marked improvement in haemodynamic parameters and short-term survival with the administration of exogenous glucocorticoids. The use of a short synacthen test may help to differentiate between patients who would benefit from glucocorticoid treatment. In the absence of this it is probably reasonable to administer glucocorticoids for a short period of time during the acute phase of the septic insult.
Theories as to the aetiology of relative adrenal insufficiency abound. These include reduced blood flow to the adrenal cortex, adrenal infarction, impaired pituitary function, the presence of circulating substances which inhibit adrenal function or action. IL-6 is a potent stimulus for ACTH secretion in humans 136 . The low levels of ACTH in patients exhibiting adrenal insufficiency may be correlated with a low IL-6 level, suggesting that a deficient Il-6 response to sepsis may result in under-stimulation of the pituitary-adrenal axis contributing to relative adrenal insufficiency.
THERAPEUTIC OPTIONS FOR COAGULOPATHY
A number of approaches have been employed to ameliorate the effects of sepsis-induced DIC. Traditional treatment of coagulopathy has involved treatment of underlying cause, administration of clotting factors if bleeding occurs, and, in the past, judicious use of heparin. Recent advances in our understanding of the pathophysiology of sepsis associated DIC have led to the development of new therapies.These are discussed below.
Protein C/Protein S system
The Protein C/Protein S system is one of the major regulatory systems of haemostasis. Protein C is vitamin K dependent zymogen of a serine protease, which is activated by thrombin/thrombomodulin complex. Protein C exhibits antithrombotic activity by inactivating activated clotting factors V and VIII, which are co-factors for the rate-limiting steps of the coagulation cascade (factor IX induced factor X activation, and activated factor X induced thrombin activation). Protein S, a co-factor in Protein C activity, is bound to a complement regulating protein (C4bBP), and markedly enhances Protein C activity. (Figure 7) .
Experimentally, prevention of activation of Protein C causes worsening of DIC and shock in baboons 137 . Infusions of activated Protein C prevented development of DIC and death. Low levels of Protein C in DIC are a result of increased consumption, caused by widespread activation of Protein C by thrombin/ thrombomodulin complex. Low levels of Protein C lead to a hypercoagulable state, and have been shown to correlate with poor outcome in DIC 72 . In patients with purpura fulminans most studies have shown a marked decrease in Protein C levels, with levels of 50% of control being associated with thrombocytopenia and correlating with poor outcome 67 . Protein C is also thought to have profibrinolytic activity. Normal Protein C levels are 0.7-1. and particularly those of under two, have lower protein C levels than adults, which may explain the rapid and fulminant progression of pupura fulminans in this age group 138 . (Figure 8 ).
Protein C concentrate has been used therapeutically as an intravenous infusion. Monoclonal antibody purified Protein C concentrate is manufactured from inactivated prothrombin complex 139 . The administration of Protein C concentrate early in the progression of purpura fulminans in children resulted in normalization of Protein C levels, a rise in fibrinogen and D-dimers (an indicator of cross-linked fibrin), and a reversal of coagulopathy 140 . No side-effects to Protein C administration have been noted 141, 142 . Potential benefits of Protein C therapy may include attenuation of the Schwartzman reaction, as seen in rabbit models 143 , anticoagulation by destroying activated factors V and VIII, and limitation of the procoagulopathic cascade which leads to fibrin microdeposition. Also, by inducing fibrinolysis and removal of fibrin deposits, Protein C may improve perfusion. The optimal dose and therapeutic range for Protein C remains to be confirmed. Doses of 30 to 100 µg six hourly have been used, and very low initial Protein C levels have been corrected to levels of 100 to 150% of control. By contrast, infusion of fresh frozen plasma will only increase protein C levels by about 20 to 50% of normal values 110 , and obligates a large volume load.
Controlled studies examining the effect of Protein C on outcome have not been performed, but the use of Protein C early in meningococcaemia may help in ameliorating the hypercoagulable state, possibly reducing end-organ damage and gangrene, and if available should be considered.
Antithrombin III
Antithrombin III (AT III) is an α-2 globulin and a major modulator of the clotting cascade. It is synthesized in the liver, and exerts its major action by irreversibly inactivating thrombin. It also inactivates other serine proteases including factors IXa, Xa, XIa, and XIIa. AT III has a narrow physiologic range, with normal values being 150 µg/ml 143 (Figure 9 ).
In DIC, AT III levels are low , often falling to below 40% of normal as a result of increased consumption 142 . AT III levels fall very early in meningococcal associated DIC 142 , and levels less than 50% are related to increased mortality. A placebo controlled trial of 32 patients with sepsis-induced DIC 145 demonstrated correction of low AT III levels and DIC after infusion of 100 µg/kg/day AT III, and reduced red cell transfusion requirements. Placebo group patients had a prolonged AT III deficiency (10 days) confirming previous reports of prolonged AT III deficiency after DIC. AT III also reduced mortality by 44%, although this was not statistically significant. This finding was repeated more recently 146 .
Animal studies of E.coli sepsis have shown that high levels of AT III attenuate DIC and increase survival in baboons 147 . Despite encouraging animal study results, AT III has not been proven to confer improvement in outcome in human meningococcaemia, and its use in meningococcaemia cannot be unequivocally recommended at present 148 . Theoretically AT III treatment may be less useful than Protein C in meningococcaemia, because cytokines induce coagulopathy via the Protein C / Protein S system and AT III is independent of this 149 . The role of AT III in conjunction with heparin remains to be elucidated. 
Heparin
The use of heparin therapy to control DIC in meningococcaemia was advocated for many years. Heparin forms a complex with AT III and increases the anticoagulant activity of AT III 1000-fold. This inhibits thrombin and prevents coagulation. AT III levels fall very early in meningococcal associated DIC and the ability of heparin to prevent coagulation in the presence of low AT III levels has been questioned. Heparin therapy has not been shown improve survival in meningococcaemia 148. .
The role of heparin in meningococcaemia may be to reduce extremity and digit necrosis. Recently, a retrospective study 151 found that heparin treatment in the first 72 hours of purpura fulminans reduced the number of digits and extremities which developed necrosis. The requirements for amputation were higher in patients who did not receive heparin. The difference was not, however, statistically significant. Also, the heparin was not started until at least four hours after admission.
A study on baboons 152 found that heparin pretreatment prior to exogenous thrombin-induced DIC prevented DIC from developing. Heparin 10U/kg/hr given two hours after DIC was established did not normalize coagulation parameters, but did improve survival. AT III was not consumed in pretreated animals. As AT III levels are very low in meningococcaemia, the simultaneous use of AT III might improve the effectiveness of heparin, particularly if AT III levels were increased to >100 % of normal.
The use of low molecular weight heparins in DIC 153 was reported to improve coagulopathy better than heparin in patients with low AT III (<70% of control). Heparin has thus not been shown to decrease mortality but it may reduce the incidence of ischaemic complications in purpura fulminans.
Heparin has also been demonstrated to increase blood TNFα receptor concentration, which theoretically could obtund the development of TNFα induced cytokine effects 152 .
Prostacyclin
Prostacyclin (epoprostenol) has been used in the treatment of neonatal purpura fulminans 155, 156 . Prostacyclin is a known vasodilator and inhibitor of platelet aggregation, and its use was associated with reversal of progressive vasculitis. Prostacyclin use in meningococcaemia has been described for vasodilatation 157 , but clinical studies are lacking. Theoretically, prostacyclin may be of benefit in reducing gangrene.
Tissue Plasminogen Activator (TPA)
Fasciotomies performed in meningococcaemia with purpura fulminans reveal major vessel thrombosis and lack of bleeding. Ten per cent of patients with purpura fulminans eventually require amputation of digits and limbs. TPA is the physiologic endothelial activator of fibrinolysis responsible for local clot specific fibrinolysis. TPA may work by interfering with plasminogen activator inhibitor 1 (PAI-1), the levels of which are raised in early meningococcaemia. TPA is produced from endothelial cells, but this production is poorly sustained in meningococcaemia. Fibrinolytic therapy offers potential advantages in limb and digit salvage. TPA has been used intra-arterially in low dose (0.02-0.04mg/kg/hr) via a brachial arterial cannula to improve compromised circulation in the hands of a child with meningococcaemia 158 . More recently, use of systemic TPA infusions (0.25-0.5 mg/kg per hour) have been reported to improve peripheral perfusion in two infants with severe meningococcaemia, without any adverse haemorrhagic sequelae 159 . Theoretically, systemic TPA therapy renders the patient more vulnerable to haemorrhage, including those from vessel puncture sites. Haematoma formation associated with fibrinolytic therapy may potentiate distal ischaemia.
Plasmapheresis/whole blood exchange
The rationale for using blood "purification" techniques in meningococcaemia is quite simple. Instead of trying to block, mediate or destroy the responsible mediators, these techniques attempt to remove them and substitute them with a "clean" replacement. High cytokine levels make plasmapheresis an attractive option in meningococcaemia. Studies in animals infected with E.coli have yielded conflicting results relating to morbidity and haemodynamic changes. Plasmapheresis has been used in the treatment of meningococcaemia, and has been felt to improve outcome [160] [161] [162] [163] .
In adults, plasma exchange performed early in severe septic shock with purpura produced a better than predicted outcome (as compared to APACHE II score), with a reduction in mortality from 38% to 14% 164 . In another study, reduction in mortality compared to that predicted was observed in patients treated with either plasma exchange or blood exchange, but this was not statistically significant 165 . Although endotoxin is certainly removed during plasmapheresis, plasma endotoxin levels did not fall as compared to an historical non-treatment group. Although theoretically sound, the benefit of plasma-pheresis in terms of outcome remains inconclusive. It is generally felt that, if used, plasmapheresis should be performed as early as possible in disease.
Removal of TNFα and Il-6 during plasmapheresis has only been demonstrated in animals. Most cytokine production is at tissue level, they have a large volume of distribution, and it has been argued that removal of free plasma cytokines is only a small and probably insignificant proportion of the total 166 .
Plasmapheresis is not without risks. Insertion of large-bore intravenous access is required, which in the presence of a coagulopathy is hazardous. In addition to removing endotoxin and cytokines, a number of beneficial blood components are also removed. These include immunoglobulins, clotting factors and cellular elements, as well as drugs, including antibiotics. Introduction of blood-borne infectious agents, as well as allergic reactions to foreign proteins may occur. Death rates relating to plasmapheresis are 3 per 10,000 167 . These are mainly anaphylactic in origin. Plasmapheresis has been used as a single treatment, or repeatedly if the patient is still critically ill. Clinical indications for repeated exchanges and optimum frequency and volume of exchange required are not known in meningococcaemia. However, as an adjunct to treatment in critically ill patients with meningococcaemia, plasmapheresis should be considered, provided realistic expectations of its value are held 168.
Haemofiltration
There are a number of studies documenting the removal of cytokines, particularly TNFα, using haemofiltration, in patients needing haemofiltration for renal failure. There is probably an advantage in using haemofiltration instead of haemodialysis in septic patients, because cytokines are removed instead of being generated by the procedure 169, 170 . The clinical significance of this is not certain, but haemofiltration may produce clinically important blood purification 171 .
Extracorporeal membrane oxygenation (ECMO)
There has been some recent interest in the use of ECMO to treat patients with severe refractory meningococcaemia 173 , in whom escalating doses of inotropes have failed to maintain blood pressure. Good outcomes were reported using veno-arterial ECMO for 43-48 hours, but as yet convincing evidence for benefit from ECMO and the indications for its use remain to be established.
Regional anaesthetic blockade
Both continuous caudal and epidural blockade have been used successfully to improve perfusion to the lower limbs in cases of meningococcaemia 174, 175 . The mechanism is thought to be by reducing sympathetic tone in vessels which are partially occluded by local vasospasm in reponse to release of vasoactive mediators. The use of these methods is limited because they are contraindicated in patients who are cardiovascularly unstable, have bacteraemia, and in those with coagulopathy.
Surgical management
Morbidity of meningococcaemia has usually been thought of in terms of neurological outcome. As the rate of meningococcal infection is increasing and as modern techniques of intensive care have improved survival in meningococcaemia, so the number of patients confronting life-long disability as a result of amputations, or those requiring extensive plastic surgery, has increased. This area of outcome has been neglected in terms of research, although 176 one study found that 12% of patients with meningococcaemia developed purpura fulminans, and all had lesions affecting at least one limb. Skin necrosis occurred by about 18 hours. Of these patients, 73% survived, all of whom needed multiple skin grafting. Of these survivors, 63% needed amputations, and nearly half of these were on more than one limb.
The gangrene almost never follows a uniform pattern of anatomic vascular distibution 177 . Surgical management of ischaemic complications of purpura fulminans involves waiting until a clear demarcation between viable and nonviable tissue develops before debridement. A bone scan can be useful in demarcating between viable and nonviable tissue 177 . Debridement of necrotic tissue and the use of escharotomies to improve perfusion in cases of circumferential necrosis may be required early in purpura fulminans.
CHEMOPROPHYLAXIS.
The rationale for treating close contacts of patients who develop meningococcal infections is that persons who live and sleep in close proximity, for example the same house, barracks, gaol etc, are 500-1000 times more likely to develop disease than the population at large 178 . Despite this, the individual risk is still very low 179 . The practice is to prescribe antibiotics not only to prevent bacterial breaching of host defences in the carrier, but also to eradicate bacteria from the nasopharynx, thus preventing spread. Antibiotics which are secreted into the nasopharyngeal mucosa, and to which N.meningitidis is sensitive, are chosen. In all confirmed outbreaks, except those involving group B, it is wise to give tetravalent vaccine (vaccine against groups A, C, W135, Y) to nonimmunised contacts, because immunity develops rapidly. There is no vaccine for group B. Antibacterial chemoprophylaxis is inadequate treatment for invasive disease and close contacts must be advised to seek prompt medical help at the earliest onset of symptoms.
Sulphadiazine was the first drug used for chemoprophylaxis, to great effect in 1940s and 1950s. The emergence of sulphadiazine resistant N.meningitidis in 1960s led to the use of rifampicin, which eradicates nasopharyngeal meningococcus in 90% of carriers. Current recommendations from the Royal Australasian College of Physicians are to administer 20 mg/kg (10 mg/kg to neonates) rifampicin once daily for two days to all household contacts, "mouth kissing" contacts, persons who have given mouth-tomouth resuscitation and to the index case when recovered. Early treatment is advised, as maximum susceptibility is within a few days. Rifampicin is contrindacated in pregnancy and liver disease. A single intramuscular dose of ceftriaxone is 97% effective at eliminating N.meningitidis from the nasopharynx of carriers 180 , and is recommended in doses of 250mg (in adults) and 125mg (in children), as an alternative. Ceftriaxone is also safe to use as chemoprophylaxis in pregnancy 181 . Ciprofloxacin has also been found to be effective 182 .
VACCINES
The current meningococcal vaccines are far from ideal. The antigenic differences in the meningococcal capsular polysaccharide form the basis for serogrouping 183 . Bactericidal antibody in the serum is directed against these capsular polysaccharides, forming the basis of using these antigens as vaccines. Purified capsular polysaccharide forms the tetravalent vaccine (against groups A, C, W135, Y), but purified vaccine produces a poor T-helper cell response, causing a short-lived antibody response. Young children less than nine months of age mount a poor immune response. Vaccines are therefore relatively ineffective in this very susceptible group. No vaccine is currently available for group B meningococcus. Newer vaccines, using lipooligosaccharide components of the meningococcal cell wall have been prepared, including some against group B. Protection rates have unfortunately been low, and preclude their clinical use at this time 184 .
CONCLUSION
Fulminant meningococcaemia carries with it a significant risk of serious morbidity and mortality. The identification of high-risk patients justifies the application of salvage therapies, particularly when the therapies themselves are of low risk. A number of scoring systems and criteria have been discussed that can be employed to identify these patients. It is unlikely any single therapy will dramatically reduce either serious morbidity or mortality. Disease progression may be so rapid that early and massive release of cytokines will have occurred prior to the use of immunotherapy. The risk of death can be reduced by early aggressive shock management including plasmapheresis and steroid therapy. The likelihood of limb gangrene can be identified early and the use of TPS combined with Protein C, Antithrombin III and low-dose heparin offers promise for these debilitating complications.
